Dr Clive Ballard just now! | ACAD Message Board Posts

ACADIA Pharmaceuticals Inc.

  ACAD website

ACAD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  15697 of 15815  at  9/19/2019 7:53:38 PM  by

longusa

The following message was updated on 9/19/2019 7:57:03 PM.

 In response to msg 15696 by  good_investor93
view thread

Re: Dr Clive Ballard just now!

To Naz,
They did not comment on efficacy within the subtypes; logic would say that with ADP being 67% of enrollees, there must have been stat sig efficacy there for sure to get an early stop; on the others, my logic would say that PDD and DLB likely saw stat sig efficacy as there is previous PhIII success in PDP; the others no way to tell, but the others are <15% of the indication.
 
An observation that just came to me when looking at those epidemiology %'s:
Looks like the relative prevalence of PDP v DLB has changed!  It used to be the DLB market was larger than PDP (they differ only in onset of symtpoms: if motor symptoms first, then PDP, if dementia symtpoms first, then DLB).  Seems that only one of those indications being approved for Nup use has changed diagnosing habits:) 
 
Sort of off-label being made to become on-label by stroke of the pen.  Well done to the diagnosing MDs.
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 423
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...